Arash Mahajerin
Pediatric Hematology-Oncology · Orange, CANPI 1033315247
Payments from drug & device makers
Across 355 payments — averaging $741.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$94K
- Genentech USA, Inc.$81K
- Spark Therapeutics, Inc.$51K
- Genentech, Inc.$16K
- Kedrion Biopharma, Inc.$6K
- Novo Nordisk$5K
- plus $10K from 13 others
Across 9 payments — averaging $1511.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$14K
What the payments were for
- Consulting fees$69,82428%
- Speaking & faculty fees$132,49453%
- Grants$4,7862%
- Travel & lodging$29,95812%
- Food & beverage$11,8745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 149 | $94,487 |
| Genentech USA, Inc. | 88 | $81,114 |
| Spark Therapeutics, Inc. | 69 | $51,112 |
| Genentech, Inc. | 11 | $15,846 |
| Kedrion Biopharma, Inc. | 2 | $6,000 |
| Novo Nordisk | 3 | $4,786 |
| F. Hoffmann-la Roche AG | 3 | $4,044 |
| Sanofi | 4 | $2,683 |
| Kedrion Biopharma Inc. | 1 | $1,200 |
| Grifols Shared Services North America, Inc. | 11 | $1,095 |
| Apellis Pharmaceuticals, Inc. | 4 | $300 |
| Tersera Therapeutics LLC | 1 | $257 |
| Amneal Pharmaceuticals LLC | 1 | $204 |
| Grifols USA, LLC | 1 | $62 |
| Amgen(2 entities) | 2 | $41 |
| Novartis | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$83,429
- ULTOMIRIS$23,252
- Albuked$7,200
- KOATE$7,200
- GAMMAKED$7,200
- KEDRAB$7,200
- RhoGAM Ultra-Filtered PLUS$7,200
- SOLIRIS$3,596
- Thrombate III$677
- Empaveli$123
How this compares
$263,312 in reported general payments places this provider in the 75th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Orange
- Elyssa RubinOrange$1.1M
- van HuynhOrange$996K
- Mariko SatoOrange$694K
- Diane NugentOrange$652K
- Vanessa Salinas-LunaOrange$538K
- Beth WingerSan Francisco$8.6M
- James GellerSan Diego$7.8M
- Norman LacayoPalo Alto$5M
- Alan WayneLos Angeles$3.8M
- Ami ShahPalo Alto$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.